Reuters logo
2 months ago
BRIEF-Nordic Nanovector: Single dose Betalutin still shows promising efficacy and safety in recurrent iNHL
June 14, 2017 / 10:27 AM / 2 months ago

BRIEF-Nordic Nanovector: Single dose Betalutin still shows promising efficacy and safety in recurrent iNHL

June 14 (Reuters) - NORDIC NANOVECTOR ASA:

* SINGLE DOSE BETALUTIN® CONTINUES TO SHOW PROMISING EFFICACY AND SAFETY IN RECURRENT INDOLENT NHL PATIENTS

* SINGLE DOSE BETALUTIN® CONTINUES TO SHOW PROMISING EFFICACY AND SAFETY IN RECURRENT INDOLENT NHL PATIENTS

* NORDIC NANOVECTOR - DATA CONTINUE TO SUPPORT COMPANY'S STRATEGY IN BETALUTIN'S DEVELOPMENT AND INTENT TO INITIATE OUR PIVOTAL PHASE 2 PARADIGME STUDY, IN SECOND HALF OF 2017

* 64% OVERALL RESPONSE RATE (ORR) AND 28% COMPLETE RESPONSES (CR) IN 47 EVALUABLE PATIENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below